Summary

The role of low-dose aspirin as primary prevention among individuals who are at high risk for cardiovascular disease is controversial. Given the greater risk for cardiovascular events among individuals with diabetes, antiplatelet therapy has appeal as a way to reduce the risk of thrombi and subsequent ischemic events in both the primary and secondary setting.